Amphastar Pharmaceuticals, Inc. (AMPH): Richard K Prins , director of Amphastar Pharmaceuticals, Inc. sold 3,200 shares on May 17, 2016. The Insider selling transaction was reported by the company on May 19, 2016 to the Securities and Exchange Commission. The shares were sold at $13.56 per share for a total value of $43,391.36 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 19, 2016, Diane G. Gerst (EVP, QA & Regulatory Affairs) sold 1,427 shares at $13.97 per share price.On Mar 21, 2016, Richard K Prins (director) sold 2,400 shares at $11.25 per share price.Also, On Dec 17, 2015, Rong Zhou (EVP, Production) sold 772 shares at $14.29 per share price.On Dec 17, 2015, Michael A Zasloff (director) sold 30,770 shares at $14.20 per share price.
Amphastar Pharmaceuticals Inc: On Thursday, May 19, 2016 heightened volatility was witnessed in Amphastar Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $13.99 and hit $14.32 on the upside , eventually ending the session at $14.28, with a gain of 1.56% or 0.22 points. The heightened volatility saw the trading volume jump to 3,55,184 shares. The 52-week high of the share price is $18.3 and the company has a market cap of $640 M . The 52-week low of the share price is at $10.5.
Company has been under the radar of several Street Analysts.Amphastar Pharmaceuticals Inc is Reiterated by Needham to Buy while Lowering the Price Target of the company shares to $ 20 from a previous price target of $21 . The Rating was issued on May 10, 2016.
Amphastar Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing manufacturing marketing and selling technically-challenging generic and injectable and inhalation products. The Company has two operational segments: finished pharmaceutical products and active pharmaceutical ingredients (API products). The finished pharmaceutical products segment manufactures markets and distributes enoxaparin Cortrosyn naloxone lidocaine jelly as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 17 products and is developing a portfolio of approximately 13 generic and eight injectable and inhalation product candidates. In addition to its marketed products it has a pipeline of approximately 21 generic and product candidates in various stages of development which target a variety of indications.